GlassScriptPhysician profile
Ahuva Jamison Cices
NPI 1578096251
$78,450.04
in general payments reported to CMS, 2019-2025
35 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $57.22 · 2021: $645 · 2022: $854 · 2023: $3,930 · 2024: $20K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $3,704 · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,260.00 |
| Food and Beverage | $27,862.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,523.00 |
| Travel and Lodging | $3,704.38 |
| Education | $401.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16,623.85 | 2024-2025 | |
| Genzyme Corporation | $15,619.14 | 2023-2025 | |
| Incyte Corporation | $8,054.52 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $5,132.35 | 2023-2025 | Nemluvio, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $5,083.90 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $4,710.78 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $3,204.77 | 2023-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $2,986.59 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $1,616.66 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $1,565.46 | 2023-2024 | Vtama |
| Merck Sharp & Dohme LLC | $1,562.42 | 2025 | |
| Almirall LLC | $1,531.56 | 2025 | Seysara, Klisyri |
| Regeneron Healthcare Solutions, INC. | $1,385.75 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,383.62 | 2023-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $1,325.36 | 2024-2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $786.68 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $622.87 | 2024-2025 | Leqselvi, Winlevi, Ilumya |
| Botanix Sb INC | $600.91 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $549.66 | 2024-2025 | Tremfya |
| Amgen INC. | $348.72 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.63 | 2023 | Spevigo |
| Celgene Corporation | $223.48 | 2023-2024 | Zeposia |
| Verrica Pharmaceuticals INC. | $189.26 | 2024-2025 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $178.18 | 2024-2025 | Entyvio |
| Regeneron Pharmaceuticals, INC. | $166.20 | 2025 | Dupixent |
| Journey Medical Corporation | $38.78 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $24.96 | 2025 | Valchlor |
| Blueprint Medicines Corporation | $22.62 | 2025 | |
| Lnhc, INC | $20.17 | 2025 | Zelsuvmi |
| Novo Nordisk INC | $20.00 | 2025 | Wegovy |
| Insmed, INC. | $17.38 | 2025 | |
| Biofrontera INC. | $15.73 | 2025 | Bf-Rhodoled |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahuva Cices listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.